FR2806626B1 - Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues - Google Patents

Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues

Info

Publication number
FR2806626B1
FR2806626B1 FR0003673A FR0003673A FR2806626B1 FR 2806626 B1 FR2806626 B1 FR 2806626B1 FR 0003673 A FR0003673 A FR 0003673A FR 0003673 A FR0003673 A FR 0003673A FR 2806626 B1 FR2806626 B1 FR 2806626B1
Authority
FR
France
Prior art keywords
prevention
expression
treatment
function
cell cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0003673A
Other languages
English (en)
Other versions
FR2806626A1 (fr
Inventor
Serge Timsit
Pauline Cavelier
Ari Yehezekiel Ben
Michel Khrestchatisky
Laurent Meijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0003673A priority Critical patent/FR2806626B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU4429201A priority patent/AU4429201A/xx
Priority to CA002403714A priority patent/CA2403714A1/fr
Priority to AU2001244292A priority patent/AU2001244292B2/en
Priority to JP2001568429A priority patent/JP2003527428A/ja
Priority to PCT/FR2001/000850 priority patent/WO2001070231A2/fr
Priority to IL15180001A priority patent/IL151800A0/xx
Priority to EP01917205A priority patent/EP1265602A2/fr
Publication of FR2806626A1 publication Critical patent/FR2806626A1/fr
Priority to ZA200207448A priority patent/ZA200207448B/en
Priority to US10/251,297 priority patent/US20030060397A1/en
Application granted granted Critical
Publication of FR2806626B1 publication Critical patent/FR2806626B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0003673A 2000-03-22 2000-03-22 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues Expired - Lifetime FR2806626B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0003673A FR2806626B1 (fr) 2000-03-22 2000-03-22 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
EP01917205A EP1265602A2 (fr) 2000-03-22 2001-03-21 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigu s
AU2001244292A AU2001244292B2 (en) 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
JP2001568429A JP2003527428A (ja) 2000-03-22 2001-03-21 急性神経損傷治療又は予防用の細胞周期に係わるタンパク質の発現又は機能変調物質の使用
PCT/FR2001/000850 WO2001070231A2 (fr) 2000-03-22 2001-03-21 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aiguës
IL15180001A IL151800A0 (en) 2000-03-22 2001-03-21 Use of substances modulating the expression of the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
AU4429201A AU4429201A (en) 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
CA002403714A CA2403714A1 (fr) 2000-03-22 2001-03-21 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neuralesaigues
ZA200207448A ZA200207448B (en) 2000-03-22 2002-09-17 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries.
US10/251,297 US20030060397A1 (en) 2000-03-22 2002-09-20 Method of treating and preventing acute neural lesions with substances that modulate the expression or function of a protein involved in the cell cycle and pharmaceutical preparations containing such substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0003673A FR2806626B1 (fr) 2000-03-22 2000-03-22 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues

Publications (2)

Publication Number Publication Date
FR2806626A1 FR2806626A1 (fr) 2001-09-28
FR2806626B1 true FR2806626B1 (fr) 2003-11-28

Family

ID=8848391

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0003673A Expired - Lifetime FR2806626B1 (fr) 2000-03-22 2000-03-22 Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues

Country Status (9)

Country Link
US (1) US20030060397A1 (fr)
EP (1) EP1265602A2 (fr)
JP (1) JP2003527428A (fr)
AU (2) AU2001244292B2 (fr)
CA (1) CA2403714A1 (fr)
FR (1) FR2806626B1 (fr)
IL (1) IL151800A0 (fr)
WO (1) WO2001070231A2 (fr)
ZA (1) ZA200207448B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
GB201217621D0 (en) * 2012-10-02 2012-11-14 Univ Leuven Kath Anticonvulsant activity of gsk-3b inhibitors
WO2016164371A1 (fr) * 2015-04-07 2016-10-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Méthodes pour induire la division cellulaire de cellules post-mitotiques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3731293A (en) * 1992-02-24 1993-09-13 Smithkline Beecham Corporation Protein kinase c inhibitor
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
GB9521322D0 (en) * 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
NZ338108A (en) * 1997-03-03 2004-12-24 Univ Texas Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections using roscovitine and olomoucine
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
EP0911634A1 (fr) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Regulateurs de CDK-2 et leurs utilisations pharamaceutiques
ATE355841T1 (de) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
CN1128149C (zh) * 1998-02-26 2003-11-19 阿旺蒂斯制药公司 6,9－二取代的2－[反－(4－氨基环己基)氨基]嘌呤
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
ATE301123T1 (de) * 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten

Also Published As

Publication number Publication date
EP1265602A2 (fr) 2002-12-18
AU4429201A (en) 2001-10-03
AU2001244292B2 (en) 2005-09-22
WO2001070231A3 (fr) 2002-06-20
ZA200207448B (en) 2004-03-25
US20030060397A1 (en) 2003-03-27
CA2403714A1 (fr) 2001-09-27
JP2003527428A (ja) 2003-09-16
WO2001070231A2 (fr) 2001-09-27
IL151800A0 (en) 2003-04-10
FR2806626A1 (fr) 2001-09-28

Similar Documents

Publication Publication Date Title
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR2869541B1 (fr) Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
FR2746641B1 (fr) Utilisation d'un extrait d'au moins une iridacee dans le traitement des rides
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
FR2745016B1 (fr) Composition pour une lotion adoucissante, utilisation de la lotion pour le traitement d'un produit papetier absorbant et produit papetier absorbant ainsi traite
HK1019560A1 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv.
DE69930410D1 (de) Infrarotabbildung zum nachweis von bestandteilen in körperpflegeprodukten
FR2733684B1 (fr) Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2786390B1 (fr) Cotyle de correction pour emploi dans le traitement de pathologies de la hanche
FR2773070B1 (fr) Compositions pour le traitement des matieres keratiniques contenant l'association d'un polymere zwitterionique et d'une silicone non-volatile et insoluble dans l'eau
FR2792835B3 (fr) Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR2806626B1 (fr) Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2839254B1 (fr) Valet d'aide pour l'habillage ou le deshabillage notamment des personnes souffrant d'un handicape et vetement associe
FR2765106B1 (fr) Utilisation de tanins reticules en presence de proteines non reticulees avec les tanins comme agents cosmetiques pour ameliorer le lissage de la peau et/ou pour l'obtention d'un effet astringent
FR2721930B1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
FR2751637B1 (fr) Cellule d'electrocoagulation pour le traitement d'effluents
FR2829760B1 (fr) Procede de preparation d'acides alpha-(phenyl)cinnamique et/ou de leurs derives, et leur utilisation dans une composition cosmetique
DZ3449A1 (fr) Composition sous forme d'emulsion appropriee pour le traitement de l'hyperhidrose et/ou bromhidrose plantaire.
FR2774596B1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
TQ Partial transmission of property
ST Notification of lapse

Effective date: 20141128

D3 Ip right revived

Effective date: 20150424

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19